Jakub Hlavka

Title(s)	Research Assistant Professor
School	USC Sol Price School of Public Policy
Address	635 Downey Way University Park Campus Los Angeles CA 90089
Phone	+1 213 821 6113
vCard	Download vCard

Biography

Education and Training

Pardee RAND Graduate School, Santa Monica, CA	PhD	Public Policy Analysis: Health Economics
Georgetown University , Washington D.C.	MA	International Affairs, Technology Policy
University of Economics, Prague, Czech Republic	BSc.	International Trade

Awards and Honors

Aspen Institute Central Europe	2017		Aspen Young Leader
St Gallen Symposium	2015		Leader of Tomorrow

Overview

Jakub Hlávka, PhD, is a Research Assistant Professor in the Health Policy and Management Department of the Price School of Public Policy and Schaeffer Center for Health Policy & Economics, University of Southern California. His research interests include innovative payment for healthcare, health system reform, emerging therapies and the study of inequality.

Prof. Hlávka completed his PhD at the Pardee RAND Graduate School where he studied innovative payment approaches for emerging treatments like cell and gene therapies, specializing in cardiovascular conditions. At RAND, he also co-authored studies in national security, aerospace and emerging technologies and has served in research and consulting roles at the intersection of research finance, intellectual property, national security and governance at Genentech, the Fraunhofer Society, RAND Europe, Czech Government and the Czech Ministry of Finance. Dr. Hlávka holds degrees from Georgetown University and the University of Economics in Prague.

Prof. Hlávka teaches graduate-level health economics at the Sol Price School of Public Policy at USC.

Interests

Health Economics, Healthcare Finance, Policy Analysis, Technology and Competition Policy, Biotechnology, Access to Healthcare, Inequality, Emerging Technologies

Websites

	USC Schaeffer Center profile
	Google Sites page
	USC Faculty Directory

In The News

U.S. health care system unprepared to move future Alzheimer's treatment into rapid clinical use (11/15/2017)

ORNG Applications

Faculty Mentoring

Featured Content

Twitter

Bibliographic

Publications

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.

Altmetrics Details

PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.

Access to Disease-Modifying Alzheimer's Therapies: Addressing Possible Challenges Using Innovative Payment Models. Value Health. 2022 Jul 05. Hlávka JP, Tysinger B, Yu JC, Lakdawalla DN. PMID: 35803845; PMCID: PMC9813270.

View in: PubMed Mentions: Fields:
Dru Drug Therapy Pub Public Health
Addressing Challenges to Alternative Payment Models for New Alzheimer's Disease Therapies for US Commercial Payers. Pharmacoeconomics. 2022 07; 40(7):647-652. Hl?vka JP, Lavelle TA, Neumann PJ, Lin PJ. PMID: 35553029.

View in: PubMed Mentions: 1 Fields:
Dru Drug Therapy Pha Pharmacology
Translation:Humans
The economics of alternative payment models for pharmaceuticals. Eur J Health Econ. 2021 Jun; 22(4):559-569. Hl?vka JP, Yu JC, Goldman DP, Lakdawalla DN. PMID: 33725260; PMCID: PMC8169601.

View in: PubMed Mentions: 1 Fields:
Hea Health Services Pub Public Health
Translation:Humans
The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis. Appl Health Econ Health Policy. 2020 10; 18(5):669-677. Hl?vka JP, Mattke S, Wilks A. PMID: 32090302; PMCID: PMC7483141.

View in: PubMed Mentions: 1 Fields:
Hea Health Services Pub Public Health
Translation:Humans
Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment. Rand Health Q. 2019 May; 8(3):2. Hlavka JP, Mattke S, Liu JL. PMID: 31205802; PMCID: PMC6557037.

View in: PubMed Mentions: 25
Biosimilar Cost Savings in the United States: Initial Experience and Future Potential. Rand Health Q. 2018 Mar; 7(4):3. Mulcahy AW, Hlavka JP, Case SR. PMID: 30083415; PMCID: PMC6075809.

View in: PubMed Mentions: 49
A New Model for Pricing Drugs of Uncertain Efficacy. NEJM Catalyst. 2018. Erik Snowberg Dana P. Goldman, Karen Van Nuys, Wei-Han Cheng, Jakub P. Hlávka, Luca Pani, Sylvain Chassang . View Publication.
Toward a Sustainable Blood Supply in the United States. 2016. Andrew W Mulcahy, Kandice Kapinos, Brian Briscombe, Lori Uscher-Pines, Ritika Chaturvedi, Spencer R Case, Jakub Hlávka, Benjamin M Miller. View Publication.